CITIUS ONCOLOGY, INC.

TenX Keane Acquisition Corp., trading on Nasdaq under the ticker TENK, is a blank-check company that completed its IPO in 2021 with a focus on the healthcare sector. Sponsored by TenX Keane LLC, the vehicle pursued a business combination with Citius Oncology, Inc., an oncology-focused biopharmaceutical company being spun out of Citius Pharmaceuticals. The S-1/A amendment filed on September 12, 2022 reflects ongoing registration activity related to the proposed de-SPAC transaction, advancing Citius Oncology toward a public listing through the combination. The filing underscores continued deal progression in the healthcare SPAC space during that period. Sign up for full data, filings history, and deal timelines on SpacDesk.